Pregabalin
DrugPregabalin capsules taken twice a daily (150-600mg/day)
NCT Number: NCT01202227
The purpose of this study is to assess the safety of the long-term use of pregabalin at doses up to 600 mg/day in patients with central neuropathic pain (post spinal cord injury pain, post stroke pain, and multiple sclerosis pain).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Chubu Rosai Hospital, Nagoya, Aichi-ken, Japan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
for subjects to be shifted from Study A0081107
Inclusion criteria
for subjects to be new participants in this study
Exclusion criteria
Pregabalin capsules taken twice a daily (150-600mg/day)
Time frame: Baseline, Weeks 4, 20, 36, 52, and 53
Number of participants who had peripheral edema in lower extremities. Edema was categorized as follows: trace, pitting 1 (lower leg), 2 (lower leg to knee), and 3 (above knee and /or presacral edema).
Time frame: Baseline, Weeks 4, 20, 36, 52, and 53
Number of participants who had facial or periorbital edema.
Time frame: Baseline, Weeks 4, 20, 36, 52, and 53
Number of participants who had generalized or abdominal edema.
Time frame: Baseline, Weeks 4, 20, 36, 52, and 53
DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.
Time frame: Baseline, Weeks 4, 20, 36, 52, and 53
DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.
Time frame: Baseline, Weeks 4, 20, 36, 52, and 53
DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.
Time frame: Baseline, Weeks 4, 20, 36, 52, and 53
DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.
Time frame: Baseline, Weeks 4, 20, 36, 52, and 53
DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.
Time frame: Baseline, Weeks 4, 20, 36, 52, and 53
DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.
Time frame: 53 weeks
Number of participants who had normal visual field at baseline and showed abnormal result after the study treatment, assessed by confrontational visual field test (neurological examination).
Time frame: 53 weeks
Worsening of the condition relative to baseline was reported as deteriorated. Assessment categories are as follows: normal or abnormal for Cranial Nerve Function, Mental State, and Coordination; normal, mild, moderate, or severe ataxia for Gait; none/absent, normal, or hyper-reflexic for Deep Tendon Reflexes; absent or present for Abnormal Reflexes; normal, mild, moderate, or severe weakness for Muscle Strength; slight, more marked, or considerable increase, or affected parts rigid in flexion or extension for Muscle Tone; absent or present for Sensory Function.
Time frame: Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52
The Sheehan-STS is an 8-item prospective rating scale that tracks treatment-emergent suicidal ideation and behaviors. Participants who reported a score of ≥1 (5-point scale ranging from 0: not at all to 4: extremely) for Item 2, 3, 4 or 5 of the Sheehan-STS prognostic scale is considered to have suicidal ideation as the scores are mapped to Category 4 (suicide ideation) of the Columbia Classification Algorithm of Suicide Assessment.
Time frame: Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52
The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.
Range: 0 to 45 for total score. Change = observation mean minus baseline mean. Negative change indicated improvement.
Time frame: Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52
The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.
Range: 0 to 33 for sensory score. Change = observation mean minus baseline mean. Negative change indicated improvement.
Time frame: Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52
The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.
Range: 0 to 12 for affective score. Change = observation mean minus baseline mean. Negative change indicated improvement.
Time frame: Baseline, Week 52
The mBPI-10 is a self administered questionnaire that assesses pain interference with functional activities over the past week. These items are measured on an 11 point scale, ranging from "does not interfere" (0) to "completely interferes" (10). A composite score, the Pain Interference Index, will be calculated by averaging the 10 items that comprise the scale.
Change = observation mean at Week 52 minus baseline mean.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain (Post Spinal Cord Injury Pain, Post Stroke Pain, And Multiple Sclerosis Pain)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01659541
Central Nervous System Diseases, Cough
Cleveland, Ohio, United States
View Trial DetailsNCT00116337
Central Nervous System Diseases, Cough
Cleveland, Ohio, United States
View Trial DetailsNCT04460872
Androgen Deficiency, Bone Diseases
Gainesville, Florida, United States
View Trial DetailsNCT00995215
Central Nervous System Diseases, Cough
Cleveland, Ohio, United States
View Trial Details